Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

Company Overview

Xenon Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs. Its lead asset, XEN1101, is an orally administered potassium channel opener being evaluated for the treatment of focal epilepsy, while other programs target sodium and calcium channel modulators for migraine prophylaxis and pain management. Xenon has established strategic collaborations with academic institutions and contract research organizations to conduct global Phase 1 and Phase 2 studies, with trial sites spanning North America and Europe. Throughout its development efforts, the company leverages translational biomarkers and electrophysiology to guide clinical dosing and patient selection.

Founded in 1999 and headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals trades on the Nasdaq under the ticker XENE. Over its history, the company has transitioned from a technology licensee to a fully integrated drug developer, expanding its team of medicinal chemists, pharmacologists and clinical specialists. Xenon is led by President and Chief Executive Officer C. Scott Myers, whose experience in neuroscience drug development supports the company’s mission to advance therapies for patients with unmet medical needs worldwide.

Key Stats

• Today's Range: $39.16 to $40.17
• 50-Day Range: $30.50 to $40.15
• 52-Week Range: $26.74 to $46.00
• Volume: 537,272 shs
• Average Volume: 751,665 shs
• Market Capitalization: $3.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.30
• Consensus Rating: Moderate Buy

Xenon Pharmaceuticals Stock Analysis - MarketRank™

Xenon Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 561st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xenon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Xenon Pharmaceuticals has a consensus price target of $53.30, representing about 34.6% upside from its current price of $39.61.

Amount of Analyst Coverage

Xenon Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.10) to ($3.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xenon Pharmaceuticals is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xenon Pharmaceuticals is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xenon Pharmaceuticals has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.13% of the outstanding shares of Xenon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Xenon Pharmaceuticals has recently increased by 1.88%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xenon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Xenon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.13% of the outstanding shares of Xenon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Xenon Pharmaceuticals has recently increased by 1.88%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.74

News Sentiment

Xenon Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Xenon Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

Only 5 people have searched for XENE on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,004,000.00 in company stock.

Percentage Held by Insiders

Only 4.07% of the stock of Xenon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XENE Stock Analysis - Frequently Asked Questions

How have XENE shares performed this year?

Xenon Pharmaceuticals' stock was trading at $39.20 on January 1st, 2025. Since then, XENE stock has increased by 1.0% and is now trading at $39.61.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Monday, August, 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.04.
Read the conference call transcript.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 10/04/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XENE
• CIK: 1582313
• Web: www.xenon-pharma.com
• Phone: (604) 484-3300
• Fax: 604-484-3450
• Employees: 210
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Xenon Pharmaceuticals: $53.30
• High Price Target: $67.00
• Low Price Target: $43.00
• Potential Upside/Downside: +34.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$234.33 million
• Net Margins: N/A
• Pretax Margin: -3,767.93%
• Return on Equity: -38.50%
• Return on Assets: -36.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.14
• Quick Ratio: 15.14

Sales & Book Value

• Annual Sales: $7.50 million
• Price / Sales: 407.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.90 per share
• Price / Book: 4.00

Miscellaneous

• Outstanding Shares: 77,106,000
• Free Float: 73,968,000
• Market Cap: $3.05 billion
• Optionable: Optionable
• Beta: 1.14